Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Yuichi Hori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6281-0998; OpenAlex author ID A5035758142, A5113493351. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
15
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Establishment of Gemcitabine-resistant Mouse Pancreatic Ductal Adenocarcinoma Cell Line and Possible Therapeutic Agents. Last author DOI 10.21873/anticanres.18076↗
  2. Novel orthotopic patient-derived xenograft model using human pancreatic cancer tissue fragments to recapitulate distant metastasis and cancer-related hypercoag… Last author DOI 10.1007/s00795-025-00425-3↗
  3. Exosomes in ascites from patients with human pancreatic cancer enhance remote metastasis partially through endothelial-mesenchymal transition. Last author DOI 10.1016/j.pan.2023.04.002↗
  4. Pancreatic cancer cell-derived exosomes induce epithelial-mesenchymal transition in human pancreatic cancer cells themselves partially via transforming growth … Last author DOI 10.1007/s00795-022-00321-0↗
  5. Effectiveness of Photodynamic Screening Using 5-Aminolevulinic Acid for the Diagnosis of Pancreatic Cancer. First author DOI 10.21873/anticanres.14347↗
  6. Xenografts Derived From Patients' Ascites Recapitulate the Gemcitabine Resistance Observed in Pancreatic Cancer Patients. First author DOI 10.1097/mpa.0000000000001438↗
  7. Identification of a novel subpopulation of tumor-initiating cells from gemcitabine-resistant pancreatic ductal adenocarcinoma patients. Last author DOI 10.1371/journal.pone.0081283↗
  8. Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells. Last author DOI 10.1159/000325538↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kumiko Miyashita · 4 shared papers, 2022–2026 · strength 0.88
  2. Kazuya Shimizu · 6 shared papers, 2011–2025 · strength 0.77
  3. Ai Kimoto · 2 shared papers, 2022–2023 · strength 0.33
  4. Takuma Miura · 1 shared paper, 2025 · strength 0.25
  5. Fumiya Nakayama · 1 shared paper, 2022 · strength 0.16
  6. Ken Sasai · 1 shared paper, 2019 · strength 0.10
  7. Tomoo Itoh · 1 shared paper, 2019 · strength 0.10
  8. Akihito Machinaga · 1 shared paper, 2019 · strength 0.10
  9. Tsukasa Ikeura · 1 shared paper, 2020 · strength 0.10
  10. Makoto Takaoka · 1 shared paper, 2020 · strength 0.10
  11. Hideaki Miyoshi · 1 shared paper, 2020 · strength 0.10
  12. Kazuichi Okazaki · 1 shared paper, 2020 · strength 0.10
  13. Hiroshi Yokozaki · 1 shared paper, 2011 · strength 0.03
  14. Okito Hashimoto · 1 shared paper, 2011 · strength 0.03
  15. Yonson Ku · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.